Cargando…
Detectability of Plasma-Derived Circulating Tumor DNA Panel in Patients Undergoing Primary Treatment for Uveal Melanoma
PURPOSE: To investigate the presence of plasma circulating tumor DNA (ctDNA) in patients with uveal melanoma during and after primary tumor treatment. METHODS: Detectability and variant allele frequency of ctDNA were assessed using a 129-oncogene panel using next-generation deep sequencing and hybri...
Autores principales: | Francis, Jasmine H., Barker, Christopher A., Brannon, A. Rose, Canestraro, Julia, Robbins, Melissa, Swartzwelder, Christina E., Levine, Sara, Law, Crystal, Berger, Michael F., Shoushtari, Alexander, Abramson, David H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766787/ https://www.ncbi.nlm.nih.gov/pubmed/36525262 http://dx.doi.org/10.1167/iovs.63.13.17 |
Ejemplares similares
-
Prognostic Factors Five Years After Enucleation for Uveal Melanoma
por: Dogrusöz, Mehmet, et al.
Publicado: (2020) -
Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin
por: Brouwer, Niels J., et al.
Publicado: (2021) -
Release of Cell-Free Tumor DNA in the Plasma of Uveal Melanoma Patients Under Radiotherapy
por: Kim, Viktoria, et al.
Publicado: (2023) -
ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells
por: Kaochar, Salma, et al.
Publicado: (2018) -
PRiMeUM: A Model for Predicting Risk of Metastasis in Uveal Melanoma
por: Vaquero-Garcia, Jorge, et al.
Publicado: (2017)